Carilex Medical (ROCO:7726) Operating Income: NT$-41.7 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7726 Carilex Medical Inc ROCO:7726
36 GF Score
Price NT$32.15
! 5 Warning Signs
View Full Analysis

What is Carilex Medical Operating Income?

Carilex Medical ROCO:7726 36 Operating Income is NT$-41.7 Mil as of Jun. 2026. GuruFocus rates ROCO:7726 with a GF Score™ of 36/100. The stock has 5 warning signs investors should review.

Carilex Medical's Operating Income for the six months ended in Jun. 2026 was NT$2.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-41.7 Mil.

Warning Sign:

Carilex Medical Inc has recorded a loss in operating income at least once over the past 3 years.

Operating Margin % is calculated as Operating Income divided by its Revenue. Carilex Medical's Operating Income for the six months ended in Jun. 2026 was NT$2.5 Mil. Carilex Medical's Revenue for the six months ended in Jun. 2026 was NT$193.5 Mil. Therefore, Carilex Medical's Operating Margin % for the quarter that ended in Jun. 2026 was 1.30%.

Carilex Medical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Carilex Medical's annualized ROC % for the quarter that ended in Jun. 2026 was 1.99%. Carilex Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 6.99%.


Carilex Medical  (ROCO:7726) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Carilex Medical's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=5.034 * ( 1 - 0% )/( (267.959 + 237.387)/ 2 )
=5.034/252.673
=1.99 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=533.955 - 55.56 - ( 224.274 - max(0, 221.832 - 432.268+224.274))
=267.959

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=527.124 - 83.607 - ( 206.13 - max(0, 221.713 - 436.273+206.13))
=237.387

Note: The Operating Income data used here is two times the semi-annual (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Carilex Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=12.824/( ( (53.904 + max(142.302, 0)) + (39.757 + max(130.874, 0)) )/ 2 )
=12.824/( ( 196.206 + 170.631 )/ 2 )
=12.824/183.4185
=6.99 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(88.282 + 95.998 + 23.029) - (55.56 + 0 + 9.447)
=142.302

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(110.673 + 95.33 + 22.216) - (83.607 + 0 + 13.738)
=130.874

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Carilex Medical's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=2.517/193.463
=1.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Carilex Medical Operating Income Related Terms


Carilex Medical Operating Income Historical Data

* Premium members only.

The historical data trend for Carilex Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carilex Medical Operating Income Chart

Carilex Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial 52.25 17.57 55.38 3.03 -42.76

Carilex Medical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 4.44 -1.41 1.43 -44.19 2.52
ROCO:7726
36GF Score
Carilex Medical Inc ROCO:7726
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carilex Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-41.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of NT$-41.7 Mil mean?
Carilex Medical (ROCO:7726) has a Operating Income of NT$-41.7 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Carilex Medical and its competitors.
Is Carilex Medical's Operating Income too high?
Carilex Medical's current Operating Income is NT$-41.7 Mil. Overall, Carilex Medical has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's Operating Income compare to ABT and SYK?
Carilex Medical's Operating Income of NT$-41.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Carilex Medical and its competitors. Carilex Medical's current Operating Income is NT$-41.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current Operating Income of NT$-41.7 Mil. The current Operating Income is NT$-41.7 Mil. Carilex Medical's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current Operating Income is NT$-41.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Carilex Medical Business Description

Address No.77, Keji 1st Road, Guishan District, Taoyuan, TWN, 33383
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
36GF Score

Get the complete analysis for ROCO:7726

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.15
Price